post similar previous post centers study risperidone add ssri treatment depression current post focuses failure authors disclose conflicts interest advance online publication article examined author listing financial support lead author mark hyman rapaport lists four grants chairmanship janssen funded study according earlier abstract version study curious rapaport list janssen financial supporter rapaport alone failure disclose nemeroff last author keller fifth author clearly conflicting interests declared let start nemeroff editor journal neuropsychopharmacology article appeared familiar journal conflict interest policy states part time submission author must disclose involvement financial otherwise might potentially bias work information listed acknowledgements appear end manuscript noted authors cover letter policy pretty clear nemeroff significant conflict interest case journal clinical psychiatry supplement conflicts interest section mentions among nemeroff quite numerous funding sources nemeroff received grant research support janssen consultant janssen member speakers bureau guessed janssen company marketing risperdal supplement derived planning roundtable supported educational grant janssen medical affairs nemeroff penned review article reflected favorably upon risperidone well drugs pretty clear conflict interest editor nemeroff enforce journal policies upon course first time behavior occurred read similar failure enforce editorial policies involving nemeroff wait nemeroff actually violated another journal policies one duplicate publication data neuropsychopharmacology author instructions page right nemeroff name editor journal see following submission representation neither manuscript data previously published except abstract currently consideration publication nemeroff aforementioned journal clinical psychiatry supplement wrote less five paragraphs describing risperidone add study data later published neuropsychopharmacology neuropsychopharmacology editorial policy study data published earlier except abstract form nemeroff wrote much longer abstract supplement paid janssen yet felt free flout editorial policy regarding prior publication course comes addition egregious failure disclose conflicts interest penalty behavior one might ask accusation editor violated conflict interest policy shall referred acnp ethics committee consideration investigation ethics committee shall report findings recommendations publications committee council action editor found guilty violating conflict interest policy subject sanction including forfeiture editorship worry nemeroff one step ahead game chose resign editorship previous scandal involving pimping vagus nerve stimulation therapy feel free read nemeroff state leaving editor position result vns debacle timing seems reflect coincidence summarize briefly nemeroff blatant conflict interest declare also editor journal article appeared disclose coi addition ignored journal prohibition prior publication data editor obviously know much better indeed difficult believe oversight appears nemeroff playing role marketer risperidone opposed carrying duties editor martin keller supplement journal clinical psychiatry mentioned keller listed received honoraria janssen advisory board member janssen keep mind whatever work conducted planning roundtable upon supplement based also funded janssen yet mention financial support janssen provided neuropsychopharmacology article apparently perhaps due nemeroff earlier brush spotlight regarding marketing vns therapy journal edits article blatant conflicts interest disclosed authors thought better conflict interest issue corrigendum correction displayed november print edition neuropsychopharmacology lists disclosures nemeroff keller rapaport obtaining article online access likely true people find correction included pages article eventually correction picked medline many readers notice add failure disclose conflicts interest shifting authorship line mentioned earlier see i feeling little skeptical course given nemeroff past ethical issues entirely surprising last chapter tale regarding risperidone augmentation study data analysis told shortly